Liquidia Corporation (LQDA)

Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600June 5, 2026 7:25 PM
PR Newswire (US) NEW YORK, June 5, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 22, 2026, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from S&P MidCap 400 and S&P SmallCap 600 are no longer representative of the mid-cap and small-cap market space, respectively. Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective DateIndex Name       ActionCompany NameTickerGICS SectorJune 22, 2026S&P 500AdditionMarvell TechnologyMRVLInformation TechnologyJune 22, 2026S&P 500DeletionPool CorpPOOLConsumer DiscretionaryJune 22, 2026S&P 500AdditionFlexFLEXInformation TechnologyJune 22, 2026S&P 500DeletionThe Campbell's CompanyCPBConsumer StaplesJune 22, 2026S&P MidCap 400AdditionRokuROKUCommunication ServicesJune 22, 2026S&P MidCap 400DeletionFlex FLEXInformation TechnologyJune 22, 2026S&P MidCap 400AdditionCoeur MiningCDEMaterialsJune 22, 2026S&P MidCap 400DeletionBellRing Brands BRBRConsumer StaplesJune 22, 2026S&P MidCap 400AdditionSemtechSMTCInformation TechnologyJune 22, 2026S&P MidCap 400DeletionCotyCOTYConsumer StaplesJune 22, 2026S&P MidCap 400AdditionSanminaSANMInformation TechnologyJune 22, 2026S&P MidCap 400DeletionConcentrix CNXCIndustrialsJune 22, 2026S&P MidCap 400AdditionViavi Solutions VIAVInformation TechnologyJune 22, 2026S&P MidCap 400DeletionBlackbaud BLKBInformation TechnologyJune 22, 2026S&P SmallCap 600AdditionPoolPOOLConsumer DiscretionaryJune 22, 2026S&P SmallCap 600DeletionEmbecta EMBCHealth CareJune 22, 2026S&P SmallCap 600AdditionThe Campbell's CompanyCPBConsumer StaplesJune 22, 2026S&P SmallCap 600DeletionUniversal Health Realty Trust UHTReal EstateJune 22, 2026S&P SmallCap 600AdditionCotyCOTYConsumer StaplesJune 22, 2026S&P SmallCap 600DeletionSemtechSMTCInformation TechnologyJune 22, 2026S&P SmallCap 600AdditionConcentrix CNXCIndustrialsJune 22, 2026S&P SmallCap 600DeletionSanmina SANMInformation TechnologyJune 22, 2026S&P SmallCap 600AdditionBlackbaudBLKBInformation TechnologyJune 22, 2026S&P SmallCap 600DeletionViavi SolutionsVIAVInformation TechnologyJune 22, 2026S&P SmallCap 600AdditionCredit Acceptance CACCFinancialsJune 22, 2026S&P SmallCap 600DeletionOxford IndustriesOXMConsumer DiscretionaryJune 22, 2026S&P SmallCap 600AdditionLazardLAZFinancialsJune 22, 2026S&P SmallCap 600DeletionGogoGOGOCommunication ServicesJune 22, 2026S&P SmallCap 600AdditionEastern BanksharesEBCFinancialsJune 22, 2026S&P SmallCap 600DeletionPRA GroupPRAAFinancialsJune 22, 2026S&P SmallCap 600AdditionWesbancoWSBCFinancialsJune 22, 2026S&P SmallCap 600DeletionInsteel IndustriesIIINIndustrialsJune 22, 2026S&P SmallCap 600AdditionWarby ParkerWRBYConsumer DiscretionaryJune 22, 2026S&P SmallCap 600DeletionEthan Allen InteriorsETDConsumer DiscretionaryJune 22, 2026S&P SmallCap 600AdditionNicolet BanksharesNICFinancialsJune 22, 2026S&P SmallCap 600DeletionCytek BiosciencesCTKBHealth CareJune 22, 2026S&P SmallCap 600AdditionLiquidia LQDAHealth CareJune 22, 2026S&P SmallCap 600DeletionMonroMNROConsumer DiscretionaryJune 22, 2026S&P SmallCap 600AdditionRush Street InteractiveRSIConsumer DiscretionaryJune 22, 2026S&P SmallCap 600DeletionVital FarmsVITLConsumer StaplesJune 22, 2026S&P SmallCap 600AdditionUnited States Lime & MineralsUSLMMaterialsJune 22, 2026S&P SmallCap 600DeletionCable OneCABOCommunication ServicesJune 22, 2026S&P SmallCap 600AdditionInvenTrust PropertiesIVTReal EstateJune 22, 2026S&P SmallCap 600DeletionForward AirFWRDIndustrialsABOUT S&P DOW JONES INDICESS&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spglobal.com/spdji/en/.FOR MORE INFORMATION:S&P Dow Jones Indices
index_services@spglobal.comMedia Inquiries
spdji.comms@spglobal.com View original content:https://www.prnewswire.com/news-releases/marvell-technology-and-flex-set-to-join-sp-500-others-to-join-sp-midcap-400-and-sp-smallcap-600-302793159.htmlSOURCE S&P Dow Jones Indices Original: Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

Liquidia (LQDA) Shares Rise After Strong Q1 Earnings and Revenue BeatMay 11, 2026 10:10 AM
IH Market News Liquidia Corporation (NASDAQ:LQDA) shares gained nearly 3% in premarket trading on Monday after the biopharmaceutical company reported first-quarter results that exceeded analyst expectations on both earnings and revenue.The company posted adjusted earnings per share of $0.52, beating the consensus estimate of $0.37 by $0.15. Revenue Boosted by Strong YUTREPIA Sales Quarterly revenue totaled $132.86 million, comfortably above analyst expectations of $116.62 million.Liquidia said net product sales from YUTREPIA — its inhaled treprostinil powder therapy for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease — reached approximately $129.9 million during the quarter.The company noted that since YUTREPIA’s launch in June 2025, the treatment has generated more than 4,500 unique patient prescriptions and has been used to treat roughly 3,750 patients through April 30, 2026. Profitability Continues to Improve Liquidia reported its third consecutive profitable quarter, posting net income of $52.9 million and adjusted EBITDA of $71.2 million.“In its third full quarter on the market, YUTREPIA continued to demonstrate sustained uptake in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, consistent with its growing adoption as the preferred inhaled prostacyclin of choice,” said Chief Executive Officer Dr. Roger Jeffs.Total revenue of $132.9 million also included approximately $3.0 million in service revenue tied to a profit-sharing agreement with Sandoz related to Treprostinil Injection sales.The company had reported no product sales during the first quarter of 2025. Operating Expenses Rise Alongside Commercial Expansion Research and development expenses increased to $12.6 million from $7.0 million a year earlier, primarily driven by additional clinical spending tied to the L606 development program.Selling, general and administrative expenses rose to $46.9 million from $30.1 million in the prior-year period, reflecting increased personnel costs and commercialization spending associated with the YUTREPIA launch. Cash Position Strengthens Liquidia ended the quarter with cash and cash equivalents of $222.8 million as of March 31, 2026, up from $190.7 million at the end of 2025.Liquidity Services stock price Original: Liquidia (LQDA) Shares Rise After Strong Q1 Earnings and Revenue Beat

Looks like you may have been wrong! 

LQDA under $10

LQDA 10Q due 3/13

LQDA another 52 week high

And a day later... another new 52 week high.
A couple of weeks ago, BofA securities raised their price target from $13 to $15. Looks like they will have to raise it again.

LQDA new 52 week high

Looks like a short squeeze for LQDA today. Nice Christmas present.

Historic short interest:

You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch

Settlement Date Short Interest Percent Change
Average Daily Share Volume Days to Cover

01/31/2023 2,658,953 (7.66) 444,904 5.98
01/13/2023 2,879,384 (5.27) 533,632 5.40
12/30/2022 3,039,697 24.71 554,219 5.48
12/15/2022 2,437,325 (16.04) 638,343 3.82
11/30/2022 2,902,877 13.83 336,342 8.63
11/15/2022 2,550,166 (25.51) 409,963 6.22
10/31/2022 3,423,367 6.15 628,188 5.45
10/14/2022 3,224,962 (6.66) 399,148 8.08
09/30/2022 3,455,141 (0.33) 792,391 4.36
09/15/2022 3,466,521 37.77 2,576,549 1.35
08/31/2022 2,516,217 22.45 2,786,398 1.00
08/15/2022 2,054,960 0.68 2,336,698 1.00
07/29/2022 2,041,040 12.23 4,815,096 1.00
07/15/2022 1,818,618 5.86 325,677 5.58
06/30/2022 1,717,938 47.18 1,419,433 1.21
06/15/2022 1,167,230 (24.85) 778,151 1.50
05/31/2022 1,553,242 44.23 1,668,452 1.00
05/13/2022 1,076,900 (3.07) 647,509 1.66
04/29/2022 1,110,986 (6.74) 696,201 1.60
04/14/2022 1,191,248 13.25 982,786 1.21
03/31/2022 1,051,863 6.83 495,412 2.12
03/15/2022 984,626 (1.68) 628,521 1.57
02/28/2022 1,001,417 (8.42) 445,508 2.25
02/15/2022 1,093,527 (5.45) 307,947 3.55
*** missing data
12/15/2021 606,877 5.02 323,008 1.88
11/30/2021 577,894 (19.12) 540,301 1.07
11/15/2021 714,517 (1.20) 1,426,508 1.00
10/29/2021 723,213 0.31 338,789 2.13
10/15/2021 720,950 5.56 282,621 2.55
09/30/2021 682,963 3.62 214,797 3.18
09/15/2021 659,095 (2.28) 136,645 4.82
08/31/2021 674,478 (2.96) 189,615 3.56
08/13/2021 695,023 (6.98) 247,833 2.80
07/30/2021 747,184 (4.13) 225,645 3.31
07/15/2021 779,363 (7.60) 255,395 3.05
06/30/2021 843,424 (44.22) 730,055 1.16
06/15/2021 1,511,961 (12.40) 342,332 4.42
05/28/2021 1,725,947 (7.06) 449,958 3.84
05/14/2021 1,856,983 2.13 374,906 4.95
04/30/2021 1,818,174 (16.06) 409,956 4.44
04/15/2021 2,166,018 8.01 463,251 4.68
03/31/2021 2,005,431 (1.31) 788,431 2.54
03/15/2021 2,032,094 62.85 993,009 2.05
02/26/2021 1,247,832 29.54 1,939,000 1.00
02/12/2021 963,284 (16.18) 1,590,564 1.00
01/29/2021 1,149,239 (3.56) 2,119,176 1.00
01/15/2021 1,191,622 (12.41) 493,619 2.41
12/31/2020 1,360,412 17.85 918,901 1.48

Liquidia (NASDAQ:LQDA) Coverage Initiated by Analysts at Bank of America
https://www.defenseworld.net/2022/05/26/liquidia-nasdaqlqda-coverage-initiated-by-analysts-at-bank-of-america.html

Robert A. Lippe Buys 29,628 Shares of Liquidia Co. (NASDAQ:LQDA) Stock
https://www.defenseworld.net/2022/05/26/robert-a-lippe-buys-29628-shares-of-liquidia-co-nasdaqlqda-stock.html

Historic short interest:

You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch

Settlement Date Short Interest Percent Change
Average Daily Share Volume Days to Cover

12/15/2021 606,877 5.02 323,008 1.88
11/30/2021 577,894 (19.12) 540,301 1.07
11/15/2021 714,517 (1.20) 1,426,508 1.00
10/29/2021 723,213 0.31 338,789 2.13
10/15/2021 720,950 5.56 282,621 2.55
09/30/2021 682,963 3.62 214,797 3.18
09/15/2021 659,095 (2.28) 136,645 4.82
08/31/2021 674,478 (2.96) 189,615 3.56
08/13/2021 695,023 (6.98) 247,833 2.80
07/30/2021 747,184 (4.13) 225,645 3.31
07/15/2021 779,363 (7.60) 255,395 3.05
06/30/2021 843,424 (44.22) 730,055 1.16
06/15/2021 1,511,961 (12.40) 342,332 4.42
05/28/2021 1,725,947 (7.06) 449,958 3.84
05/14/2021 1,856,983 2.13 374,906 4.95
04/30/2021 1,818,174 (16.06) 409,956 4.44
04/15/2021 2,166,018 8.01 463,251 4.68
03/31/2021 2,005,431 (1.31) 788,431 2.54
03/15/2021 2,032,094 62.85 993,009 2.05
02/26/2021 1,247,832 29.54 1,939,000 1.00
02/12/2021 963,284 (16.18) 1,590,564 1.00
01/29/2021 1,149,239 (3.56) 2,119,176 1.00
01/15/2021 1,191,622 (12.41) 493,619 2.41
12/31/2020 1,360,412 17.85 918,901 1.48

Needham On Liquidia Price Target Raise: Positive On 'Tentative FDA Approval For The Treatment Of Pulmonary Arterial Hypertension' Given Yutrepia Meets All FDA Standards For Approval; Sees Co. 'In A Much Stronger Position' Ahead Of March 2022 Trial

LQDA

LQDA looking good!!!

Hey fingers. I too picked up a bunch of cheap shares at this price point. LQDA!!!

i seem to be the ONLY real poster here. I just have to say that this will be over 4.50 again soon. Glad this little interest right now whilst i buy all these cheap 2.70 to 2.89 shares. LQDA

yea nice website. great 2 year chart at the bottom of this channel. we might be good for 100 to 500% increases from here IMO. LQDA

Agreed and same. I was reading through the company’s website earlier today. Very impressive. LQDA!!!

yea very few posters here. im getting anything 8 can under 2.90! great nasdaq stock chart! LQDA

Hi fingers. I’m new to LQDA. Seems like we are at a great entry point. LQDA!!!

bought more at 2.89

im in with a starter at 2.91. will hold however long. they might recover? LQDA

I'm in 3.04

bought in today

This is current news today. Nov 13th stockholders meeting.

RESEARCH TRIANGLE PARK, N.C, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced it has rescheduled its special meeting of stockholders, which was originally scheduled for October 21, 2020, to be held at 4:30 p.m., Eastern Time, on November 13, 2020. The special meeting will be a virtual meeting conducted solely online via live webcast and can be attended by visiting www.meetingcenter.io/287587626.

As previously announced, on October 16, 2020, the Company received an unsolicited offer to enter into a License Agreement for the Company’s LIQ861 product candidate (the “Alternative Proposal”). The Alternative Proposal was conditioned upon the Company terminating the Agreement and Plan of Merger, dated as of June 29, 2020, by and among the Company, RareGen, LLC, Liquidia Corporation, Gemini Merger Sub I, Inc., Gemini Merger Sub II, LLC, and PBM RG Holdings, LLC (the “Merger Agreement”). On November 1, 2020, the Company’s board of directors (the “Board of Directors”) has determined that the Alternative Proposal does not constitute a Superior Proposal and the Company subsequently informed the counterparty that it is terminating discussions with respect to such Alternative Proposal.

Accordingly, the Board of Directors has unanimously reaffirmed its recommendations that the Company’s stockholders vote “FOR” each proposal being submitted to a vote of the Company’s stockholders at the Special Meeting.

Not sure but there is NO bad news. The only news 11/2 today is to announce the investor conference call moved to Nov 13th.

Liquidia to Report Third Quarter 2020 Financial Results and Provide Corporate Update on November 6, 2020
4:15 pm ET October 30, 2020 (Globe Newswire) Print

LQDA why the big drop this AM? Bad news coming?

"SUPERIOR PROPOSAL" > Jason Adair

Vice President, Corporate Development and Strategy

LQDA

Just half that is enough for me, the rest will be his-story.

Just 22 months ago LQDA was over 25.00 > "Show me the money!" (offer).

We will soon find out how superior it is.

Another run to $25.00+ > SUPERIOR OFFER!!!!!

and then we have news today that the offer is superior and that is why they postponed the shareholder meeting.

Liquidia Technologies Inc. said it received an unsolicited offer for a license agreement for its LIQ861 product candidate.

Any thoughts on the United Theraputics / MannKind collaboration for similar PAH dry powder inhaler?

Also, anyone know what caused the price decline from Feb 2019 to Jan 2020?

* * $LQDA Video Chart 12-26-2019 * *

Link to Video - click here to watch the technical chart video

Already in it. Beat him to it

clay is watching LQDA just may be a play of the day.

* * $LQDA Video Chart 12-24-2019 * *

Link to Video - click here to watch the technical chart video

Well I really regret not buying this

I rarely buy at IPO but I find that the significant backers and the positive clinical trials will make LQDA a good candidate for anyone interested in new pharma (neopharmacy?). As the article below also stipulates, the dilution is low and brings the attraction of this one up. I'm in to see what 2019 will bring.

https://seekingalpha.com/article/4196391-liquidia-ipo-phase-3-clinical-stage-interested-bill-gates-foundation

IPO went through today with expected pps. Although a rise early morning, it quickly fell from that. Interesting read on where the company is going in regards to their tech, however, revenues are negative as expected from a company in developmental phases.